Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen

British Journal of Cancer

Volumn 85, Issue 1, 2001, Pages 129-136

  Forsberg, G ^a   Ohlsson, L ^a   Brodin, T ^a   Bjork P ^a   Lando, P A ^a   Shaw, D ^b   Stern, P L ^b   Dohlsten, M ^c  

^a Active Biotech Research AB   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; ONCOFETAL ANTIGEN; RECOMBINANT PROTEIN; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; CYTOLYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TARGETING; T LYMPHOCYTE;

ANIMALS; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CLONING, MOLECULAR; CYTOKINES; ESCHERICHIA COLI; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, SCID; RECOMBINANT FUSION PROTEINS; SUPERANTIGENS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035816233     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1891     Document Type: Article

References (47)

1. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A
2. Overview of clinical trials employing antibody-targeted superantigens
3. HPV 16 infection and progression of cervical intra-epithehal neoplasia: Analysis of HLA polymorphism and HPV 16 E6 sequence variants
4. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia
5. Man-made superantigens: Tumour selective agents for T-cell-based therapy
6. Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane
7. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells
8. Antibody engineering
9. Two subsets of human CD4+ T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies
10. Monoclonal antibody-targeted superantigens: A different class of anti-tumour agents
11. Immunopharmacology of the superantigen Staphylococcal enterotoxin A in T-cell receptor Vb3 transgenic mice
12. Monoclonal antibody-superantigen fusion proteins: Tumour specific agents for T cell based tumour therapy
13. Antibody targeted superantigens are potent inducers of tumour-infiltrating T lymphocytes in vivo
14. Immuno-therapy of human colon cancer by antibody targeted superantigens
15. Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli
16. Implications for immunosurveillance of altered HLA class 1 phenotypes in human tumours
17. Traztusumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
18. Genetically engineered superantigens as tolerable antitumor agents
19. Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR+ mononuclear leukocytes and freshly prepared leukemia cells
20. A 72 KD trophoblast glycoprotein defined by a monoclonal antibody
21. Isolation and characterization of 5T4, a tumour-associated antigen
22. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II
23. Recombinant antibody fragments
24. Recombinant antibody constructs in cancer therapy
25. Staphylococcal enterotoxin microbial superantigens
26. Antibody-targeted superantigen therapy induces tumour-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma
27. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
28. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
29. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients
30. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats
31. Cytokine biosynthesis by tumor infiltrating T lymphocytes from human non small-cell lung carcinoma
32. Monoclonal antibodies in cancer therapy
33. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
34. Long-term survival and complete cures of B16-melanoma carrying animals after therapy with tumour targeted IL-2 and SEA
35. The attraction of proteins for small molecules and ions
36. Crystal structure of the superantigen staphylococcal enterotoxin type A
37. Treatment with tumour-reactive Fab-IL-2 and Fab-Staphylococcal enteroxin A fusion proteins leads to sustained T cell activation and long-term survival of mice with established tumours
38. Immunohistological distribution of 5T4 antigen in normal and malignant tissues
39. The expression of 5T4 antigen in colorectal and gastric carcinoma
40. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma
41. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance
42. Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies
43. Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study
44. Characterization of antibody binding to cell surface antigens using plasma membrane-bound plate assay
45. Man-made antibodies
46. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer